Neoplasma Vol.53, p.26-29, 2006
|
| Title: The significance of soluble CD138 in diagnosis of monoclonal gammopathies
|
| Author: V., MAISNAR
; M., TOUSKOVA
; M., TICHY
; J., KREJSEK
; L., CHROBAK
; J., VOGLOVA
; J., MALY
; |
|
Abstract: Report is summary of the results of study designed to ascertain
the significance of soluble CD138 (sCD138) assessment
in patients with different monoclonal gammopathies. Previous
studies have shown that sCD138 is shed from the surface of
myeloma cells into serum and that this marker is a new independent
prognostic parameter in multiple myeloma.
In presented study was evaluated serum sCD138 level in 14 patients
with monoclonal gammopathy of undetermined significance
(MGUS) and in 17 patients with multiple myeloma (MM),
all MM patients were treated by high-dose chemotherapy
regimen with subsequent autologous transplantation of peripheral
blood stem cells. To determine the sCD138 level we
used a rapid and simple ELISA procedure.
The mean serum sCD138 level of patients with MGUSwas 32 ng/ml
(range: 5–128). Soluble CD138 levels were elevated
in the sera of 10 out of 17 (59%) multiple myeloma patients, the
mean baseline sCD138 concentration was 1542 ng/ml
(range: 10–17300). In spite of small number of patients the
difference between MGUS and MM group was highly statistically
significant (p<0,001). Multiple myeloma patients with high level
of sCD138 at diagnosis (cut-off value: 500 ng/ml)
had worse prognosis despite of good response to chemotherapy in
some of them (p=0.029).
It seems that determination of sCD138 can be recommended as a
helpful and reliable marker for differential diagnosis as
well as prognosis of monoclonal gammopathies.
|
|
| Keywords: soluble CD138, syndecan-1, monoclonal gammopathy, multiple
myeloma, prognosis
|
| Year: 2006, Volume: 53, Issue: |
Page From: 26, Page To: 29 |
|
|
|
|
|
 download file |
|
|
|
|
